One ALK inhibitor, crizotinib, has shown great efficacy against relapsed/refractory ALK+ ALCL in USA and European countries.[9,12] Another ALK inhibitor, alectinib, has been used for ALK+ non-small cell lung carcinoma (NSCLC)[13] and was recently approved for use in ALK+ ALCL in Japan after promising phase II study.[14] Here, we show a chemotherapy- and BV-resistant ALK+ ALCL patient with leukemic presentation who was treated with crizotinib and received allogeneic HSCT. The gene discussed is ALK; the disease is non-small cell lung carcinoma.